Why the study?
Does the excess cardiovascular morbidity and mortality in patients with rheumatoid arthritis change over time with more modern management?
Does the excess cardiovascular morbidity and mortality in patients with rheumatoid arthritis change over time with more modern management?
Despite more extensive treatment and reduced disease severity in recent decades, patients with rheumatoid arthritis continue to have a similarly elevated risk of cardiovascular morbidity and mortality compared to the general population.
Answers are grounded in this paper and cite their sources.
Elevated CV morbidity and mortality in RA persist despite modern management; leaves open whether targeted interventions can reduce this excess.
OBJECTIVE: Patients with RA have an increased risk of cardiovascular disease. Management of RA has changed substantially over time. Our aim was to evaluate changes in cardiovascular morbidity and mortality over the period of 1978-2002. METHODS: Two cohorts of consecutive patients with RA seen at outpatient clinics in Malmö, Sweden, were started in 1978 (n = 148) and 1995 (n = 161) and compared with the corresponding background population. Patients were followed for 8 years, and fatal and non-fatal cardiovascular first events were identified using two national registers, hospital discharge and cause of death. Standardized morbidity ratio (SMoR) and standardized mortality ratio (SMR), adjusted for age and sex were calculated. RESULTS: Sex distribution, age at disease onset and disease duration were similar in both groups. The 1995 cohort was more extensively treated with DMARDs and had less disease activity and disability. Total cardiovascular morbidity was increased in the 1978 cohort (SMoR 158; 95% CI 111, 225) as well as in the 1995 cohort (SMoR 168; 95% CI 118, 232). This was mainly due to an increased risk of coronary artery disease. Overall mortality was elevated in the 1978 cohort but not in the 1995 cohort. There was no change in cardiovascular excess mortality (SMR 175; 95% CI 100, 284; and 172; 100, 276 for the two cohorts, respectively). CONCLUSIONS: There were similar elevations in the incidence of cardiovascular comorbidity in RA patients, identified two decades apart compared with the general population, in spite of more extensive treatment and reduced disease severity in the more recent cohort.
No takes yet. Share an insight, caveat, or question.
Bergström et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: